LDL choelsterol
Showing 26 - 50 of 1,261
Heart Transplant Trial in Omaha (Evolocumab (Repatha))
Active, not recruiting
- Heart Transplant
- Evolocumab (Repatha)
-
Omaha, NebraskaUniversity of Nebraska Medical Center
Dec 15, 2022
Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthritis Trial in Oslo (Individually tailored diet counseling, The brief
Recruiting
- Rheumatoid Arthritis
- +2 more
- Individually tailored diet counseling
- The brief standardized 4-minute heart healthy dietary advice
-
Oslo, NorwayDiakonhjemmet Hospital
Mar 17, 2023
Qualitative Features of Atherosclerotic Plaques
Active, not recruiting
- Atherosclerotic Cardiovascular Disease
-
Riga, LatviaPauls Stradins Clinical University Hospital
Dec 5, 2022
Familial Hypercholesterolemia Trial
Not yet recruiting
- Familial Hypercholesterolemia
- (no location specified)
Apr 11, 2023
Atheroscleroses, Coronary Trial in Seoul (Rosuvastatin and Ezetimibe, Rosuvastatin)
Active, not recruiting
- Atheroscleroses, Coronary
- Rosuvastatin and Ezetimibe
- Rosuvastatin
-
Seoul, Korea, Republic of
- +1 more
Oct 1, 2022
Inclisiran on Major Adverse Cardiovascular Events in French
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- Inclisiran sodium
- +3 more
- (no location specified)
Jul 26, 2023
Cardiovascular Diseases Trial (Meal timing)
Recruiting
- Cardiovascular Diseases
- Meal timing
-
Bath, United KingdomDepartment for Health, University of Bath
Oct 10, 2022
Hypercholesterolemia Trial in Clermont-ferrand, Clermont-Ferrand, Durtol (LIMICOL, PLACEBO)
Completed
- Hypercholesterolemia
- LIMICOL
- PLACEBO
-
Clermont-ferrand, France
- +3 more
Feb 28, 2023
Hyper-low-density Lipoprotein (LDL) Cholesterolemia Trial in Izumisano-shi (180mg of ETC-1002(bempedoic acid))
Recruiting
- Hyper-low-density Lipoprotein (LDL) Cholesterolemia
- 180mg of ETC-1002(bempedoic acid)
-
Izumisano-shi, JapanRinku General Medical Center
Jan 13, 2023
Coronary Artery Disease, Dyslipidemias Trial in Yongin (a high dose of statin/ezetimib)
Recruiting
- Coronary Artery Disease
- Dyslipidemias
- a high dose of statin/ezetimib
-
Yongin, Gyeonggi-do, Korea, Republic ofYongin Severance Hospital
Jun 14, 2023
Homozygous Familial Hypercholesterolemia Trial in Worldwide (lerodalcibep, evolocumab)
Active, not recruiting
- Homozygous Familial Hypercholesterolemia
-
Evanston, Illinois
- +11 more
Jul 13, 2022
Elevated Low-Density Lipoprotein Cholesterol Trial in Herston, Adelaide, Melbourne (SNK-396 - SAD cohort, SNK-396 - MAD Cohort)
Recruiting
- Elevated Low-Density Lipoprotein Cholesterol
- SNK-396 - SAD cohort
- SNK-396 - MAD Cohort
-
Herston, Queensland, Australia
- +2 more
Jun 6, 2023
To Reduce the LDL-C Level in Hypercholesteremia Patients Trial (RN0191)
Not yet recruiting
- To Reduce the LDL-C Level in Hypercholesteremia Patients
- (no location specified)
Nov 13, 2023
Dyslipidemias, Stroke, Acute Ischemic Trial in Ansan, Seoul (combination of high-dose rosuvastatin and ezetimibe, high-dose
Recruiting
- Dyslipidemias
- Stroke, Acute Ischemic
- combination of high-dose rosuvastatin and ezetimibe
- high-dose rosuvastatin single administration
-
Ansan, Gyeonggi-do, Korea, Republic of
- +2 more
May 22, 2023
Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)
Not yet recruiting
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- Inclisiran
- Matching Placebo for Inclisiran
- (no location specified)
May 24, 2023
Hypercholesterolemia, Cardiovascular Diseases Trial in Cincinnati (lerodalcibep, evolocumab, alirocumab)
Active, not recruiting
- Hypercholesterolemia
- Cardiovascular Diseases
- lerodalcibep
- +2 more
-
Cincinnati, Ohio
- +2 more
Jul 13, 2022
Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)
Not yet recruiting
- Hypercholesterolemia
- Familial Hypercholesterolemia
- MK-0616
- Placebo
- (no location specified)
Jul 10, 2023
Categories and Attaining LDL-C Targets in Middle Eastern Adults
Not yet recruiting
- Atherosclerotic Cardiovascular Risk
- Low-density-lipoprotein (LDL) Cholesterol
- (no location specified)
Feb 16, 2023
Familial Hypobetalipoproteinemia, Familial Hypobetalipoproteinemia - Heterozygous Form Trial (Administration of deuterated
Not yet recruiting
- Familial Hypobetalipoproteinemia
- Familial Hypobetalipoproteinemia - Heterozygous Form
- Administration of deuterated compounds for kinetic study
- (no location specified)
Oct 5, 2022
Hypercholesterolemia, Familial Hypercholesterolemia Trial in Worldwide (MK-0616, Placebo)
Active, not recruiting
- Hypercholesterolemia
- Familial Hypercholesterolemia
- MK-0616
- Placebo
-
Beverly Hills, California
- +62 more
Aug 2, 2022
Hypercholesterolemia Trial in Beijing (IBI306 450mg SC Q4W, Placebo SC Q4W, IBI306 600mg SC Q6W)
Completed
- Hypercholesterolemia
- IBI306 450mg SC Q4W
- +3 more
-
Beijing, ChinaPeking University First Hospital
Apr 2, 2022
Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)
Not yet recruiting
- Hypercholesterolemia
- Familial Hypercholesterolemia
- MK-0616
- Placebo
- (no location specified)
Jul 10, 2023
LDL-cholesterol Trial in Jena (statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran)
Recruiting
- LDL-cholesterol
- statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
-
Jena, Thuringia, GermanyUniversity Hospital Jena
Oct 17, 2022
Hypercholesterolemia Trial (HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose)
Not yet recruiting
- Hypercholesterolemia
- HSK31679 low dose
- +4 more
- (no location specified)
Mar 20, 2023